| Names | |
|---|---|
| Preferred IUPAC name
(7S)-7-{[(2S,9S,9aS)-9-Hydroxy-2-(2-methylpropyl)-3-oxo-2,3,9,9a-tetrahydro-1H-imidazo[1,2-a]indol-9-yl]methyl}-6,7-dihydroquinazolino[3,2-a][1,4]benzodiazepine-5,13-dione | |
| Identifiers | |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider | |
PubChem CID
|
|
| UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C31H29N5O4 | |
| Molar mass | 535.593 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Asperlicin is a mycotoxin, derived from the fungus Aspergillus alliaceus. It acts as a selective antagonist for the cholecystokinin receptor CCKA,[1][2][3] and has been used as a lead compound for the development of a number of novel CCKA antagonists with potential clinical applications.[4][5][6][7] He et al. 1998 present a synthesis from aryl iodide and vinyl iodide.[8]
References
- ^ Chang, RS; Lotti, VJ; Monaghan, RL; Birnbaum, J; Stapley, EO; Goetz, MA; Albers-Schönberg, G; Patchett, AA; Liesch, JM; Hensens, OD; et al. (Oct 1985). "A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus". Science. 230 (4722): 177–9. PMID 2994227.
- ^ Goetz, MA; Lopez, M; Monaghan, RL; Chang, RS; Lotti, VJ; Chen, TB (Dec 1985). "Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Fermentation, isolation and biological properties". Journal of Antibiotics (Tokyo). 38 (12): 1633–7. PMID 3005212.
- ^ Liesch, JM; Hensens, OD; Springer, JP; Chang, RS; Lotti, VJ (Dec 1985). "Asperlicin, a novel non-peptidal cholecystokinin antagonist from Aspergillus alliaceus. Structure elucidation". Journal of Antibiotics (Tokyo). 38 (12): 1638–41. PMID 3841533.
- ^ Bock, MG; DiPardo, RM; Rittle, KE; et al. (October 1986). "Cholecystokinin antagonists. Synthesis of asperlicin analogues with improved potency and water solubility". J. Med. Chem. 29 (10): 1941–5. PMID 3761313.
- ^ Evans, BE; Rittle, KE; Bock, MG; DiPardo, RM; Freidinger, RM; Whitter, WL; Gould, NP; Lundell, GF; Homnick, CF; Veber, DF; et al. (Jul 1987). ""Design of nonpeptidal ligands for a peptide receptor " cholecystokinin antagonists". Journal of Medicinal Chemistry. 30 (7): 1229–39. PMID 2885419.
- ^ Van der Bent, A; Ter Laak, AM; IJzerman, AP; Soudijn, W (August 1992). "Molecular modelling of asperlicin derived cholecystokinin A receptor antagonists". Eur. J. Pharmacol. 226 (4): 327–34. PMID 1397061.
- ^ Lattmann, E; Billington, DC; Poyner, DR; Howitt, SB; Offel, M (2001). "Synthesis and evaluation of asperlicin analogues as non-peptidal cholecystokinin-antagonists". Drug Design and Discovery. 17 (3): 219–30. PMID 11469752.
- ^ Nakamura, Itaru; Yamamoto, Yoshinori (2004-02-21). "Transition-Metal-Catalyzed Reactions in Heterocyclic Synthesis". Chemical Reviews. 104 (5). American Chemical Society (ACS): 2127–2198. doi:10.1021/cr020095i. ISSN 0009-2665. PMID 15137788.
